Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Renal Cell 20Sarcoma 4Neuroendocrine Tumors 4Neoplasms 4Carcinoma, Medullary 4Carcinoma, Hepatocellular 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Kidney Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Cancer, Papillary 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Prostatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Melanoma 2Lung Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Neuroendocrine 2Carcinoma 2Adenocarcinoma, Follicular 2Wilms Tumor 1Urologic Neoplasms 1

Interventions

cabozantinib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × High Grade Neuroendocrine Neoplasms × cabozantinib × Clear all
NCT04412629 2026-04-06

Cabozantinib in High Grade Neuroendocrine Neoplasms

Washington University School of Medicine

Phase 2 Active not recruiting
35 enrolled
Endocrine

High Grade Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡